X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC) and the potential for combinations with this agent.

Read more.

source: OncLive